immucell corporation is a biotechnology company based out of portland maine. immucell's focus is to create scientifically-proven and practical products that result in a measurable economical impact on animal health and productivity in the dairy and beed industries.
Company profile
Ticker
ICCC
Exchange
Website
CEO
Michael Brigham
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
10382980
ICCC stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
10 Apr 24
424B2
Prospectus for primary offering
9 Apr 24
424B2
Prospectus for primary offering
9 Apr 24
8-K
Entry into a Material Definitive Agreement
9 Apr 24
8-K
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
9 Apr 24
S-3
Shelf registration
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Entry into a Material Definitive Agreement
27 Feb 24
8-K
ImmuCell Announces Unaudited Financial Results for
27 Feb 24
Transcripts
ICCC
Earnings call transcript
2023 Q4
28 Feb 24
ICCC
Earnings call transcript
2023 Q3
14 Nov 23
ICCC
Earnings call transcript
2023 Q2
11 Aug 23
ICCC
Earnings call transcript
2023 Q1
12 May 23
ICCC
Earnings call transcript
2022 Q4
22 Feb 23
ICCC
Earnings call transcript
2022 Q3
22 Nov 22
ICCC
Earnings call transcript
2022 Q2
12 Aug 22
ICCC
Earnings call transcript
2022 Q1
13 May 22
ICCC
Earnings call transcript
2021 Q4
23 Feb 22
ICCC
Earnings call transcript
2021 Q3
16 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm |
Cash burn (monthly) | (no burn) | 569.86 k | 394.68 k | 545.18 k | 169.25 k | 437.42 k |
Cash used (since last report) | n/a | 3.93 mm | 2.72 mm | 3.76 mm | 1.17 mm | 3.01 mm |
Cash remaining | n/a | -1.94 mm | -729.00 k | -1.77 mm | 823.70 k | -1.02 mm |
Runway (months of cash) | n/a | -3.4 | -1.8 | -3.2 | 4.9 | -2.3 |
Institutional ownership, Q2 2023
13.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 8 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 4.71 bn |
Total shares | 1.06 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 206.33 k | $1.03 bn |
Renaissance Technologies | 122.39 k | $612.00 k |
Bleichroeder | 101.59 k | $507.97 mm |
Cresset Asset Management | 100.51 k | $512.58 mm |
MS Morgan Stanley | 74.97 k | $374.87 mm |
Dimensional Fund Advisors | 64.26 k | $327.75 mm |
Shufro Rose & Co | 62.41 k | $312.04 mm |
Geode Capital Management | 45.73 k | $233.21 mm |
Empire Financial Management | 42.00 k | $210.00 mm |
Overbrook Management | 32.86 k | $164.29 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Sep 23 | David Scott Tomsche | Common stock $0.10 per value per share | Sale back to company | Acquire D | No | No | 4.7541 | 3,100 | 14.74 k | 103,606 |
28 Jun 23 | Bryan K. Gathagan | NQSO Common Stock | Grant | Acquire A | No | No | 5.11 | 15,000 | 76.65 k | 15,000 |
14 Mar 23 | David Scott Tomsche | Common Stock, $0.10 per value per share | Sale back to company | Acquire D | No | No | 5.44 | 100 | 544.00 | 100,506 |
14 Mar 23 | David Scott Tomsche | Common Stock, $0.10 per value per share | Sale back to company | Acquire D | No | No | 5.53 | 69 | 381.57 | 100,406 |
14 Mar 23 | David Scott Tomsche | Common Stock, $0.10 per value per share | Sale back to company | Acquire D | No | No | 5.53 | 100 | 553.00 | 100,337 |
14 Mar 23 | David Scott Tomsche | Common Stock, $0.10 per value per share | Sale back to company | Acquire D | No | No | 5.53 | 69 | 381.57 | 100,237 |
14 Mar 23 | David Scott Tomsche | Common Stock, $0.10 per value per share | Sale back to company | Acquire D | No | No | 5.53 | 31 | 171.43 | 100,168 |
14 Mar 23 | David Scott Tomsche | Common Stock, $0.10 per value per share | Sale back to company | Acquire D | No | No | 5.53 | 31 | 171.43 | 100,137 |
14 Mar 23 | David Scott Tomsche | Common Stock, $0.10 per value per share | Sale back to company | Acquire D | No | No | 5.53 | 69 | 381.57 | 100,106 |
14 Mar 23 | David Scott Tomsche | Common Stock, $0.10 per value per share | Sale back to company | Acquire D | No | No | 5.53 | 31 | 171.43 | 100,037 |